321 related articles for article (PubMed ID: 16153131)
1. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.
Welte R; Trotter CL; Edmunds WJ; Postma MJ; Beutels P
Pharmacoeconomics; 2005; 23(9):855-74. PubMed ID: 16153131
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
3. Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada.
Huang L; Mauskopf J; Farkouh R; Masaquel C
Expert Rev Vaccines; 2021 Jan; 20(1):59-72. PubMed ID: 33455487
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
5. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.
De Wals P; Zhou Z
Pediatr Infect Dis J; 2017 Jul; 36(7):e203-e207. PubMed ID: 28027288
[TBL] [Abstract][Full Text] [Related]
7. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
Trotter CL; Edmunds WJ
BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
Si S; Zomer E; Fletcher S; Lee J; Liew D
Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
[TBL] [Abstract][Full Text] [Related]
10. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
11. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
[TBL] [Abstract][Full Text] [Related]
12. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.
de Greeff SC; de Melker HE; Spanjaard L; Schouls LM; van Derende A
Pediatr Infect Dis J; 2006 Jan; 25(1):79-80. PubMed ID: 16395110
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
De Wals P; Deceuninck G; Boulianne N; De Serres G
JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
[TBL] [Abstract][Full Text] [Related]
14. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
15. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
Trotter CL; Ramsay ME; Kaczmarski EB
Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692
[TBL] [Abstract][Full Text] [Related]
16. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.
Tin Tin Htar M; Jackson S; Balmer P; Serra LC; Vyse A; Slack M; Riera-Montes M; Swerdlow DL; Findlow J
BMC Public Health; 2020 Dec; 20(1):1890. PubMed ID: 33298015
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
[TBL] [Abstract][Full Text] [Related]
18. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
[TBL] [Abstract][Full Text] [Related]
19. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
Trotter CL; Edmunds WJ
Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
[TBL] [Abstract][Full Text] [Related]
20. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations].
Gendrel D
Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
